SUNLENCA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Romania, United Kingdom

Active ingredients

The drug SUNLENCA contains one active pharmaceutical ingredient (API):

1 Lenacapavir UNII A9A0O6FB4H - LENACAPAVIR

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA, virus assembly and release, and capsid core formation. Read about Lenacapavir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SUNLENCA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC
SUNLENCA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AX31		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3036721, 3044854
Country: FR	Base de données publique des médicaments	Identifier(s): 62721516, 65950064
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9251, 9252
Country: IT	Agenzia del Farmaco	Identifier(s): 050232014, 050232026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095364, 1095365
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69101001, W69102001